Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
Institut Bergonié
Memorial Sloan Kettering Cancer Center
University of Rochester
Instituto do Cancer do Estado de São Paulo
Sarcoma Oncology Research Center, LLC